Key terms
About MYMD
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MYMD news
Apr 08
5:02pm ET
MyMD Pharmaceuticals Enhances Governance and Financing Structure
Mar 05
11:12am ET
MyMD Pharmaceuticals Regains Compliance with Nasdaq Rules
Mar 05
9:32am ET
MyMD Pharmaceuticals regains compliance with Nasdaq
Feb 14
7:50pm ET
MyMD Pharmaceuticals trading halted, news pending
Feb 13
5:13pm ET
MyMD Pharmaceuticals Announces Reverse Stock Split
No recent press releases are available for MYMD
MYMD Financials
Key terms
Ad Feedback
MYMD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MYMD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
